Sean P. Collins, MD, PhD

Sean P. Collins MD, PhD

University of South Florida

Tampa, Florida

Dr. Sean P. Collins, MD, PhD is a Professor and Vice Chair of Faculty Affairs in the Department of Radiation Oncology at the University of South Florida. Dr. Collins most recently served as the director of the CyberKnife Prostate Program at MedStar Georgetown University Hospital in Washington, D.C.. Dr. Collins specializes in prostate cancer. Specifically, he has treated over 2500 men with prostate cancer utilizing the CyberKnife.

Dr. Collins received his MD and PhD from the University of Michigan Scientist Training Program (MSTP), in Ann Arbor, Michigan. Dr. Collins is board certified with the American Board of Radiology in Radiation Oncology. He has been at the forefront of innovative radiation therapies, earning him recognition as a Washingtonian Top Doctor since 2015.

In addition to his clinical expertise, Dr. Collins is a prolific researcher and educator, contributing to national and international efforts to improve cancer treatment outcomes. He has published over 300 peer reviewed articles and abstracts, many of which evaluated patient reported outcomes (PRO) following prostate cancer treatment. He has obtained grant funding from the National Cancer Institute to focus on determinants of racial disparity in prostate cancer. Has served as an active member of the Alliance in Oncology Radiation Oncology and GU Committees since 2010.

He currently serves on the steering committee for two trials assessing the potential benefits of rectal spacers with prostate radiotherapy. Most recently he was selected as incoming Chair of the Programmatic Panel for the Department of Defense (DOD) Prostate Cancer Research Program. Recognized for his leadership in prostate cancer care, Dr. Collins continues to push the boundaries of cancer treatment, while mentoring the next generation of radiation oncologists.

PET Tumor Board – Case 3: 62-year-old BRCA2-Positive Prostate Cancer Survivor with PSA Recurrence

Posted by E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins MD, PhD, Sherief H. Gamie, MD and Daniel P. Petrylak, MD | Aug 2025

E. David Crawford, MD, presents a case involving a 62-year-old BRCA2-positive prostate cancer survivor with PSA recurrence.

PET Tumor Board – Case 2: A Case of a 72-year-old with Rising PSA and MRI Showing PI-RADSv2.1 Categories 4 and 5

Posted by E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins MD, PhD, Sherief H. Gamie, MD and Daniel P. Petrylak, MD | Jul 2025

E. David Crawford, MD, presents a case involving a 72-year-old with a rising PSA and suspicious MRI findings who initially delays biopsy.

Need to Know: Rapid Fire PET Tumor Board Discussions

Posted by E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins MD, PhD, Sherief H. Gamie, MD and Daniel P. Petrylak, MD | Jul 2025

E. David Crawford, MD, and a panel of experts address PSMA PET imaging in prostate cancer.

PET Tumor Board – Case 1: A Case of a 55-year-old Prostate Cancer Survivor with Rising PSA Five Years After Radical Prostatectomy

Posted by E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins MD, PhD, Sherief H. Gamie, MD and Daniel P. Petrylak, MD | Jun 2025

E. David Crawford, MD, presents a case of a 55-year-old prostate cancer survivor with rising PSA five years after radical prostatectomy.

Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls

Posted by Sean P. Collins MD, PhD | Dec 2024

Sean P. Collins, MD, PhD, shares POSLUMA, a new PSMA-specific PET imaging agent approved in May 2023 for prostate cancer.